<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The potential of radioimmunotherapy to selectively kill <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> cells is well established </plain></SENT>
<SENT sid="1" pm="."><plain>However, optimisation is required with regards to increasing <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> localisation of antibodies </plain></SENT>
<SENT sid="2" pm="."><plain>We used the PDGF-receptor inhibitor <z:chebi fb="0" ids="31690">imatinib mesylate</z:chebi> to improve <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e>-specific antibody localisation in two models of colorectal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> and correlated antibody localisation with changes to <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> microvasculature </plain></SENT>
<SENT sid="3" pm="."><plain>Mice bearing human colorectal xenografts (LS174T or SW1222) were treated with <z:chebi fb="0" ids="45783">imatinib</z:chebi> prior to administration of radiolabeled anti-CEA antibodies ((125)I-A5B7) </plain></SENT>
<SENT sid="4" pm="."><plain>Whole <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> and regional localisation of radiolabeled antibodies were measured </plain></SENT>
<SENT sid="5" pm="."><plain>Microvessel density and pericyte coverage were quantified in whole <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> and correlated with (125)I-A5B7 localisation </plain></SENT>
<SENT sid="6" pm="."><plain><z:chebi fb="0" ids="45783">Imatinib</z:chebi> increased uptake of (125)I-A5B7 in LS174T but not SW1222 <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> after 48 h (p &lt; 0.05) </plain></SENT>
<SENT sid="7" pm="."><plain><z:chebi fb="0" ids="45783">Imatinib</z:chebi> reduced microvessel density in both models (p &lt; 0.05) but reduced pericyte attachment to endothelial cells only in SW1222 xenografts (p &lt; 0.05) </plain></SENT>
<SENT sid="8" pm="."><plain><z:chebi fb="0" ids="45783">Imatinib</z:chebi> increases antibody distribution in LS174T <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e> but not SW1222 <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumours</z:e>, and this correlated to changes in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> microvessels </plain></SENT>
<SENT sid="9" pm="."><plain>Accelerated clearance of radiolabeled antibody from <z:mpath ids='MPATH_458'>normal</z:mpath> tissues in both models resulted in enhanced <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> to <z:mpath ids='MPATH_458'>normal</z:mpath> tissue ratios </plain></SENT>
<SENT sid="10" pm="."><plain>This improvement in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e>/<z:mpath ids='MPATH_458'>normal</z:mpath> tissue ratio has potential clinical benefit from a therapy and imaging perspective, and merits further investigation </plain></SENT>
</text></document>